

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent No.: 5,468,743.

Issue Date: November 21, 1995

Expiration Date: November 21, 2012

Title: IMIDAZO[2,1-B][3]BENZAZEPINE DERIVATIVES,
COMPOSITIONS AND METHOD OF USE

The Honorable David J. Kappos
The Undersecretary of Commerce for Intellectual Property
Mail Stop Hatch-Waxman Patent Extension
P.O. Box 1450
Alexandria, VA 22313-1450

RECEIVED
JUN 12 2012
PATENT EXTENSION
OPLA

Express Mail Certificate

“Express Mail” mailing number.:

EH 607061836 US


Date of Deposit

June 12, 2012

I hereby certify that an original an Application for Interim Extension of Patent Term (37 C.F.R. § 1.760), four (4) copies of such application, and a return postcard are being deposited with the United States Postal Service “Express Mail Post Office to Addressee” service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Mail Stop Patent Extension, P.O. Box 1450, Alexandria, VA 22313-1450.

CYNTHIA N. CROSSLAND

Typed or printed name of person mailing paper



Signature of person mailing paper

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent No.: 5,468,743.

Issue Date: November 21, 1995

Expiration Date: November 21, 2012

Title: IMIDAZO[2,1-B][3]BENZAZEPINE DERIVATIVES,
COMPOSITIONS AND METHOD OF USE

The Honorable David J. Kappos
The Undersecretary of Commerce for Intellectual Property
Mail Stop Hatch-Waxman Patent Extension
P.O. Box 1450
Alexandria, VA 22313-1450

RECEIVED
JUN 12 2012
PATENT EXTENSION
OPLA

APPLICATION FOR INTERIM EXTENSION OF PATENT TERM
(37 C.F.R. § 1.760)

Dear Sir:

Janssen Pharmaceutica, N.V. ("Applicant") hereby requests an Interim Patent Term Extension for a period of one (1) year as is provided under 35 U.S.C. § 156(e)(2) and 37 C.F.R. § 1.760, from November 21, 2012 until November 21, 2013 to allow for additional time for reviewing and granting Applicant's previously filed an application for patent term extension.

BACKGROUND

Applicant filed an application for patent term extension for U.S. Patent No. 5,468,743 on September 23, 2010 ("PTE Application") under 35 U.S.C. § 156. U.S. Patent No. 5,468,743 ('743 Patent) claims an active ingredient known by the USAN Name alcaftadine and the tradename LASTACRAFT™. LASTACRAFT™ received marketing approval under 37 C.F.R. on July 28, 2010 and was assigned new drug application no. 22-134.

Applicant believes that it is not likely that final approval of the PTE Application and issue of a certificate of extension will not occur prior to November 21, 2012, the expiration date of '743 Patent.

The '743 Patent is set to expire on November 21, 2012 and this petition is filed more than three (3) months prior to this expected expiration date.

FEE STATUS


Authorization is hereby made to charge the amount of \$420.00 to Deposit Account No. 10-0750/JAB0812/RTH.

Charge any additional fees required by this paper or credit any overpayment in the manner authorized above.

Four additional copies of this application are attached, making a total of five copies being submitted.

Respectfully submitted,

By:



Ruby T. Hope
Reg. No. 34,350

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-1024
Dated: June 12, 2012